C1 esterase inhibitor-mediated immunosuppression in COVID-19: Friend or foe?

C1 esterase inhibitor-mediated immunosuppression in COVID-19: Friend or foe?

From asymptomatic to severe, SARS-CoV-2, causative agent of COVID-19, elicits varying disease severities. Moreover, understanding innate and adaptive immune responses to SARS-CoV-2 is imperative since variants such as Omicron negatively impact adaptive antibody neutralization. Severe COVID-19 is, in...

Full description

Bibliographic Details
Main Authors: Melissa A. Hausburg, Jason S. Williams, Kaysie L. Banton, Charles W. Mains, Michael Roshon, David Bar-Or
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Clinical Immunology Communications
Subjects:
COVID-19
C1-INH
C1 esterase inhibitor
Complement
Inflammation
FXII
Online Access:http://www.sciencedirect.com/science/article/pii/S2772613422000130

Internet

http://www.sciencedirect.com/science/article/pii/S2772613422000130

Similar Items